Navigation Links
Pacific Biometrics Inc. Reports First Quarter Operating Results

SEATTLE, Nov. 16 /PRNewswire-FirstCall/ -- Pacific Biometrics, Inc. (OTC Bulletin Board: PBME) ("PBI" or "the Company"), a leading provider of specialty central laboratory and clinical biomarker services, today announced its operating results for the first quarter of FY2010. The Company will host an investor conference call to discuss its FY2010 first quarter operating results at 4:15 p.m. EST today (see details below).

For the three months ended September 30, 2009, revenues increased 27% to $2,301,375, compared with $1,805,042 in the first quarter of the previous fiscal year. The Company posted an operating loss of $213,708 in the most recent quarter, versus an operating loss of $213,372 in the prior-year period. The Company reported a net loss of $273,150, or $0.01 per share, in the most recent quarter, versus a net loss of $5,737, or $0.00 per share, in the corresponding period of the previous fiscal year. The increase in net loss was primarily due to the fact that in the first quarter of FY2009 the Company recorded a significant non-cash gain related to convertible debt that was then outstanding.

"We are pleased that our first quarter revenues were 27% above last year's levels," commented Ron Helm, Chairman and Chief Executive Officer of Pacific Biometrics, Inc. "Having said that, we did not reach our internal revenue goal, in part because of the early termination of several clinical studies for reasons unrelated to our performance. Unfortunately, studies are sometimes terminated unexpectedly by clinical trial sponsors, for a variety of reasons, prior to the completion of our work under the terms of the original contracts. This is simply a feature of our business. We also cannot ignore the ongoing economic difficulties that continue to impact the clinical trials industry, combined with the impact of tight credit markets on spending and investment in all sectors of our markets."

"Although our gross profit margins improved and our SG&A expense ratio declined relative to the prior-year period, we still recorded an operating loss in this year's first quarter. This reflects, in large part, the significant and ongoing investments we are making in our clinical biomarker services business, which we continue to see as a major growth opportunity going forward. Despite the decline in first quarter net income, I am pleased to report that PBI continued to generate positive cash flow from operating activities during the three months ended September 30, 2009."

"Based on our internal financial metrics, we are optimistic that our revenues for fiscal 2010 will exceed the record revenues achieved in fiscal 2009," Mr. Helm continued. "We are encouraged by the substantial requests for proposals received from new and existing customers in recent months, and I am confident that PBI's scientific, technical and operational capabilities, combined with a more aggressive business development strategy, will allow us to capture our fair share of these new contract opportunities. Also, our continued focus on biomarkers is gaining traction in a market that is experiencing significant growth in outsourced lab services and in which there are as yet no dominant industry leaders. To further capitalize on these trends, we are investing in new instrument platforms that will allow us to broaden our therapeutic areas of expertise and open up additional growth opportunities."

For additional information, see Pacific Biometrics' Annual Report on Form 10K for the fiscal year ended June 30, 2009 and the Quarterly Report on Form 10-Q for the three months ended September 30, 2009, available on the SEC's website at

Investor Conference Call

Pacific Biometrics, Inc. will host an investor conference call to discuss its first quarter FY2010 operating results, along with other relevant subjects at 4:15 p.m. EST (1:15 p.m. PST) today -- Monday, November 16, 2009.

Stockholders and other interested parties may listen to the conference call by dialing 800-860-2442 (international/local participants dial 412-858-4600) and requesting the "Pacific Biometrics, Inc. Conference Call" a few minutes before 4:15 p.m. EST on November 16, 2009. A replay of the conference call will be available one hour after the call through Monday, November 23, 2009 at 5:00 p.m. EDT by dialing 877-344-7529 (international/local participants dial 412-317-0088) and entering the Conference ID 435436.

About Pacific Biometrics, Inc. (PBI)

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, and multiplex testing.

PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol "PBME". For more information about PBI, visit the company's web site at

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release includes forward-looking statements including, but not limited to, the growth in revenues that may result from established and new services, including our biomarker services, our strategic planning and business development efforts, impacts on our financial results, our future growth, and the viability and acceptance of our products and services in the market. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, our ability to bid on and win laboratory services contracts, client changes or early terminations of studies, variability in backlog, the success of our marketing and business development efforts, competition in the industry, general economic factors in the industry, and our ability to manage growth, as well as the risks and other factors set forth in our periodic filings with the U.S. Securities and Exchange Commission (including our Form 10-K for the year ended June 30, 2009).

                        PACIFIC BIOMETRICS, INC.
                       CONSOLIDATED BALANCE SHEETS

                                          September 30,    June 30,
                   ASSETS                     2009          2009
                                            ---------     ---------
    Current assets:
        Cash and cash equivalents           $3,233,788   $1,365,406
        Short-term investments                 504,320            -
        Accounts receivable, net             1,688,386    2,238,912
        Other receivable, net                    6,500        9,000
        Inventory                              127,679      171,885
        Prepaid expenses and other assets      183,313      230,974
                                               -------      -------
              Total current assets           5,743,986    4,016,177

    Property and equipment, net                814,625      813,258

              Total assets                  $6,558,611   $4,829,435
                                            ==========   ==========


    Current liabilities:
        Accounts payable                      $511,082     $678,818
        Accrued liabilities                    421,524      660,284
        Advances from customers - current
         portion                               174,779      155,471
        Capital lease obligation - current
         portion                                64,896       62,709
        Secured note - current portion, net
         discount of $26,257                   391,117            -
                                               -------          ---
              Total current liabilities      1,563,398    1,557,282

        Advances from customers - long -
         term portion                          272,032      272,032
        Capital lease obligations - long -
         term portion                          139,239      156,309
        Secured note - long - term portion,
         net discount of $173,510            3,409,116            -
                                             ---------          ---
              Total liabilities              5,383,785    1,985,623
                                             ---------    ---------

    Commitments and contingencies                    -            -

    Stockholders' equity:
        Preferred stock, Series A convertible
         $0.01 par value, 5,000,000 shares
         authorized, 0 shares issued and
         outstanding at September 30, 2009
         and June 30, 2009                           -            -
        Common stock, $0.01 par value,
         30,000,000 shares authorized,
         19,099,539 shares issued and
         16,813,133 outstanding at September
         30, 2009, 19,099,539 shares issued
         and outstanding at June 30, 2009      192,050      190,995
        Additional paid-in capital          29,193,052   29,121,334
        Accumulated deficit                (26,741,667) (26,468,517)
        Treasury stock                      (1,468,609)           -
                                            ----------          ---
              Total stockholders' equity     1,174,826    2,843,812

              Total liabilities and
               stockholders' equity         $6,558,611   $4,829,435
                                            ==========   ==========

     The accompanying condensed notes are an integral part of these
                    consolidated financial statements.

                       PACIFIC BIOMETRICS, INC.
                                              Three Months Ended
                                                 September 30,
                                               2009        2008
                                               ----        ----

    Revenues                               $2,301,375  $1,805,042
                                           ----------  ----------

     Laboratory expenses and cost of sales  1,393,700   1,103,369
                                            ---------   ---------
            Gross profit                      907,675     701,673
                                              -------     -------

    Operating expenses:
        Selling, general and
         administrative                     1,121,383     915,045
                                            ---------     -------

    Operating loss                           (213,708)   (213,372)
                                              -------     -------

    Other income (expense):
      Interest expense                        (53,100)   (111,058)
      Gain on adjustment of embedded and
       freestanding derivatives to fair
       value                                        -     332,570
      Amortization of deferred financing
       costs - secured convertible debt             -     (18,447)
      Amortization of discount on debt         (5,958)          -
      Other income (expense)                     (384)      4,570
                                                  ---       -----
            Total other income (expense)      (59,442)    207,635

    Net loss before tax expense              (273,150)     (5,737)
                                              -------       -----

    Tax expense                                     -           -

    Net loss                                $(273,150)    $(5,737)
                                            =========     =======

    Net loss per share:                        $(0.01)     $(0.00)
                                               ======      ======

    Weighted average common shares
     outstanding, basic and diluted:       18,832,061  18,920,147
                                           ==========  ==========

       The accompanying condensed notes are an integral part of
                these consolidated financial statements.

                                PACIFIC BIOMETRICS, INC.

                                                     Three Months Ended
                                                        September 30,
                                                   2009               2008
                                                   ----               ----
    Cash flows from operating activities:
     Net loss                                  $(273,150)            $(5,737)

     Reconciliation of net loss to net cash
      provided by operating activities:
       Depreciation and amortization              75,609              53,469
       Accretion of fair value assigned
        to conversion feature and warrants             -              69,044
       Amortization of deferred financing
        costs on  secured convertible note             -              18,447
       Gain from embedded and freestanding
        derivative liabilities relating to
        secured  convertible note                      -            (332,570)
       Amortization of fair value assigned
        to repurchased shares of common stock      5,958                   -
       Net losses (gains) on investments           1,713                   -
       Warrant expense for equipment lease
        and financing                                  -               2,956
       Compensation expense
        from restricted shares and options        72,774               6,201
         Changes in assets and liabilities:
           Accounts receivable                   550,526             642,103
           Other receivable                        2,500             451,291
           Inventory                              44,206             (80,816)
           Prepaid expenses and other assets      47,661             (58,856)
           Advances from customers                19,308             121,913
           Accounts payable                     (167,736)           (388,423)
           Accrued liabilities                  (238,760)           (127,387)
                                                 -------             -------
             Net cash provided by
              operating activities               140,609             371,635
                                                 -------             -------

    Cash flows from investing activities:
     Purchases of capital equipment              (76,977)            (14,352)
     Purchases of investments                   (506,033)                  -
                                                 -------                 ---
             Net cash used in investing
              activities                        (583,010)            (14,352)

    Cash flows from financing activities:
     Payments on notes payable                         -            (598,244)
     Proceeds from loan                        4,000,000                   -
     Repurchases of common stock              (1,674,334)                  -
     Payments on capital lease
      obligations                                (14,883)            (11,416)
                                                  ------              ------
             Net cash provided by
              (used in) financing
              activities                       2,310,783            (609,660)
                                               ---------             -------

    Net increase (decrease) in cash
     and cash equivalents                      1,868,382            (252,377)
    Cash and cash equivalents,
     beginning of period                       1,365,406           1,196,310
                                               ---------           ---------

    Cash and cash equivalents,
     end of period                            $3,233,788            $943,933
                                               =========             =======

    Supplemental Information:
    Cash paid during the period
     for interest                                $85,846             $42,833
    Cash paid during the period
     for income taxes                                 $-                  $-

       The accompanying condensed notes are an integral part of
                these consolidated financial statements.

SOURCE Pacific Biometrics, Inc.

SOURCE Pacific Biometrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology news :

1. Freshwater supplies threatened in central Pacific
2. Environmental setting of human migrations in the circum-Pacific Region
3. Quakes under Pacific floor reveal unexpected circulatory system
4. Worlds largest marine protected area created in Pacific Ocean
5. New study finds most North Pacific humpback whale populations rebounding
6. Pacific coast turning more acidic
7. NOAA study shows eastern tropical pacific ocean dolphin populations improving
8. Parasites outweigh predators in Pacific Coast estuaries
9. Pacific shellfish ready to invade Atlantic
10. Robot vehicle surveys deep sea off Pacific Northwest
11. Scientists discover a new Pacific iguana
Post Your Comments:
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... Lithuania, announced today that they have entered into a multiyear collaboration to identify ... CRISPR researchers with additional tools for gene editing across all applications. , Under ...
(Date:10/11/2017)... ... October 11, 2017 , ... At its national ... Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based ... selected for membership in ARCS Alumni Hall of Fame . ASTER Labs ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
(Date:10/10/2017)... SAN DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... website as part of its corporate rebranding initiative announced today. The bold new ... broaden its reach, as the company moves into a significant growth period. , It ...
Breaking Biology Technology: